Kaken Pharmaceutical Management
Management criteria checks 3/4
Kaken Pharmaceutical's CEO is Hiroyuki Horiuchi, appointed in Jun 2020, has a tenure of 5.58 years. total yearly compensation is ¥123.00M, comprised of 56.1% salary and 43.9% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth $200.72K. The average tenure of the management team and the board of directors is 5.6 years and 3.1 years respectively.
Key information
Hiroyuki Horiuchi
Chief executive officer
JP¥123.0m
Total compensation
| CEO salary percentage | 56.10% |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5.6yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | JP¥651m |
| Jun 30 2025 | n/a | n/a | JP¥12b |
| Mar 31 2025 | JP¥123m | JP¥69m | JP¥14b |
Compensation vs Market: Hiroyuki's total compensation ($USD775.52K) is below average for companies of similar size in the US market ($USD3.31M).
Compensation vs Earnings: Insufficient data to compare Hiroyuki's compensation with company performance.
CEO
Hiroyuki Horiuchi (63 yo)
Mr. Hiroyuki Horiuchi serves as Director of Kaken Pharmaceutical Co. Ltd. since June 2016 and has been its President since June 2020. He is the Chairman of Kaken Pharmaceutical Co. Ltd.He was Chief Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 5.6yrs | JP¥123.00m | 0.020% $ 200.7k | |
| General Manager of Legal Affairs & Intellectual Property Department | less than a year | no data | no data | |
| General Manager of Corporate Communications Department | no data | no data | no data | |
| Chief Officer of Marketing & Sales Division | no data | no data | no data | |
| MD, Director of the Corporate Planning & Coordination Department and Director | 5.8yrs | no data | 0.0084% $ 83.4k | |
| Chief Officer of R&D Division and Director | no data | no data | 0.0063% $ 62.6k | |
| Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department | no data | no data | no data | |
| Deputy Chief Officer of R&D Division & Chief of Drug Research Center | no data | no data | no data | |
| Corporate Officer | no data | no data | no data | |
| Head of Clinical Development Department | no data | no data | no data | |
| General Manager of Research & Development Planning and Project Management Department | no data | no data | no data |
Experienced Management: KKPC.F's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.6yrs | JP¥123.00m | 0.020% $ 200.7k | |
| MD, Director of the Corporate Planning & Coordination Department and Director | 4.6yrs | no data | 0.0084% $ 83.4k | |
| Chief Officer of R&D Division and Director | 2.6yrs | no data | 0.0063% $ 62.6k | |
| Independent Outside Director | 5.6yrs | no data | 0.0013% $ 13.0k | |
| Independent Outside Director | 4.6yrs | no data | 0.00026% $ 2.6k | |
| Outside Audit & Supervisory Board Member | 2.6yrs | no data | 0.00026% $ 2.6k | |
| Standing Audit & Supervisory Board Member | 2.6yrs | no data | 0.015% $ 151.3k | |
| Director | 1.6yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 4.6yrs | no data | 0.0011% $ 10.5k | |
| Standing Audit & Supervisory Board Member | 3.6yrs | no data | 0.0050% $ 49.6k | |
| Independent Outside Director | 1.6yrs | no data | no data | |
| Director | less than a year | no data | no data |
Experienced Board: KKPC.F's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 08:19 |
| End of Day Share Price | 2026/01/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kaken Pharmaceutical Co., Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
| Junya Yamazaki | Jefferies LLC |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |